ATXN3L Polyclonal Antibody, AbBy Fluor-555 Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bs-4807R-BF555-100uL |
| Product Name | ATXN3L Polyclonal Antibody, AbBy Fluor-555 Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human |
| Specifications | |
| Conjugation | AbBy Fluor-555 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human ATXN3L |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 92552 |
| Subcellular location | Cell membrane |
| Synonyms | ATX3L_HUMAN; ATXN3L; Machado-Joseph disease protein 1-like; MJDL; Putative ataxin-3-like protein. |
| Background | Defects in ATXN3 are the cause of spinocerebellar ataxia type 3 (SCA3) ; also known as Machado-Joseph disease (MJD). Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA3 belongs to the autosomal dominant cerebellar ataxias type I (ADCA I) which are characterized by cerebellar ataxia in combination with additional clinical features like optic atrophy, ophthalmoplegia, bulbar and extrapyramidal signs, peripheral neuropathy and dementia. The molecular defect in SCA3 is the a CAG repeat expansion in ATXN3 coding region. Longer expansions result in earlier onset and more severe clinical manifestations of the disease. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is ATXN3L Polyclonal Antibody, AbBy Fluor-555 Conjugated (bs-4807R-BF555) validated for, and at what dilution?
bs-4807R-BF555 is validated for WB (1:300-5000); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does ATXN3L Polyclonal Antibody, AbBy Fluor-555 Conjugated (bs-4807R-BF555) react with?
Tested reactivity: Human.
How should bs-4807R-BF555 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise ATXN3L Polyclonal Antibody, AbBy Fluor-555 Conjugated (bs-4807R-BF555)?
KLH conjugated synthetic peptide derived from human ATXN3L
What are the excitation and emission wavelengths of the AbBy Fluor-555 conjugate (bs-4807R-BF555)?
AbBy Fluor-555 on bs-4807R-BF555: excitation / emission 553nm/568nm.